Additionally, Biosearch will develop cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics.
Biosearch Technologies Corporate Development director Marc Beal said IMDx’s assays, powered by BHQ probing technologies, provides a potent combination for future diagnostic tests.
Biosearch is a supplier of oligonucleotide components to the molecular diagnostics industry, while IMDx is a developer and manufacturer of clinically impactful molecular test solutions.